Latest Tuberculosis Vaccine Trial Results Show Mixed Success

For over a century, the BCG vaccine has been the only tool against tuberculosis (TB).

techBCG vaccine

concepttuberculosis

Recent April 2026 Phase 3 trials in India evaluating VPM1002 and Immuvac highlight a complex, mixed landscape in vaccine research.

eventPhase 3 trial

locationIndia

techVPM1002

techImmuvac

However, VPM1002 achieved a notable 50.4% efficacy against deadly extrapulmonary TB, and showed ~65% efficacy in children aged 6–14.

techVPM1002

Meanwhile, the M72/AS01E vaccine remains the field's frontrunner.

techM72/AS01E

Currently in Phase 3 trials, it previously demonstrated a promising 50% efficacy in preventing active TB in adults with latent infections.

eventPhase 3 trial

Instead of seeking a single 'holy grail' vaccine, researchers are moving toward precision immunization.

conceptprecision immunization

🎉

End of article

You read 6 focus sentences.

Challenge Mode

Comprehension Questions

Why is the current BCG vaccine considered limited?

It has not been shown to be safe for any age group.

It is only effective against latent TB.

Its protective effect decreases significantly as people reach adolescence and adulthood.

Reveal Answer

✓

Correct Choice

Its protective effect decreases significantly as people reach adolescence and adulthood.

What significant finding was associated with VPM1002 in the 2026 Indian trial?

It achieved 90% efficacy against all forms of pulmonary TB.

It demonstrated 50.4% efficacy against extrapulmonary tuberculosis.

It was completely ineffective in all age groups.

Reveal Answer

✓

Correct Choice

It demonstrated 50.4% efficacy against extrapulmonary tuberculosis.

What makes the M72/AS01E vaccine a major point of interest in TB research?

It has already been fully approved for global distribution.

It is the first vaccine designed specifically for infants.

It showed 50% efficacy in preventing active disease in adults with latent infections.

Reveal Answer

✓

Correct Choice

It showed 50% efficacy in preventing active disease in adults with latent infections.

How is the approach to TB vaccine development shifting according to the article?

Researchers are focusing exclusively on creating one universal vaccine.

Scientists have decided to abandon all current clinical trials.

The field is moving toward precision immunization strategies based on age and health status.

Reveal Answer

✓

Correct Choice

The field is moving toward precision immunization strategies based on age and health status.

What is a positive takeaway regarding the next-generation TB vaccine candidates?

They are cheaper to produce than the original BCG vaccine.

They are generally considered safe and well-tolerated by participants.

They have all successfully eradicated TB in clinical trials.

Reveal Answer

✓

Correct Choice

They are generally considered safe and well-tolerated by participants.

Learn faster with Ringoo apps

Trace your learning progress and get real-time feedback with interactive exercises.

App Store Google Play